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Abstract
Background—Efavirenz (EFV) has been associated with torsade de pointes despite marginal QT 
interval lengthening. Since EFV is metabolized by the cytochrome P450 (CYP) 2B6 enzyme, we 
hypothesized that EFV would lengthen the rate-corrected QT (QTcF) interval in carriers of the 
CYP2B6*6 decreased functional allele.
Objective—The primary objective of this study was to evaluate EFV-associated QT interval 
changes with regard to CYP2B6 genotype and to explore mechanisms of QT interval lengthening.
Methods—EFV was administered to healthy volunteers (n=57) as a single 600 mg dose followed 
by multiple doses to steady-state. Subjects were genotyped for known CYP2B6 alleles and ECGs 
and EFV plasma concentrations were obtained serially. Whole-cell, voltage-clamp experiments 
were performed on cells stably expressing hERG and exposed to EFV in the presence and absence 
of CYP2B6 expression.
Results—EFV demonstrated a gene-dose effect and exceeded the FDA criteria for QTcF interval 
prolongation in CYP2B6*6/*6 carriers. The largest mean time-matched differences ΔΔQTcF were 
observed at 6 hrs (14 ms; 95% CI [1; 27]), 12 hrs (18 ms; 95% CI [−4; 40] and 18 hrs (6 ms; 95% 
CI [−1; 14]) in the CYP2B6*6/*6 genotype. EFV concentrations exceeding 0.4 µg/mL 
significantly inhibited outward hERG tail currents (P<0.05).
Conclusions—This study demonstrates that homozygous carriers of CYP2B6*6 allele may be at 
increased risk for EFV-induced QTcF interval prolongation via inhibition of hERG.
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Introduction
Patients infected with human immunodeficiency virus (HIV) are at an increased risk of 
cardiovascular disorders including the ventricular tachyarrhythmia, torsade de pointes 
(TdP).1–3 Both the pathophysiology and treatment of HIV may be associated with rate 
corrected QT (QTc) interval prolongation to increase the risk for TdP.1–4 Efavirenz (EFV) is 
non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits potent and durable 
virological suppression. Due to well-documented clinical efficacy and favorable 
pharmacological properties, EFV 600 mg per day, in combination with 2 nucleoside reverse 
transcriptase inhibitors (NRTIs), has been extensively used globally as a preferred first line 
therapy for HIV treatment-naïve patients for over 15 years.5, 6
Efavirenz is generally well-tolerated, but certain patients may be at risk for serious adverse 
effects. In addition to the well-documented, concentration-dependent central nervous system 
(CNS) symptoms and hepatic injury,7–10 EFV has been reported to induce QTc interval 
prolongation and TdP.11 In a thorough QTc (TQT) study, steady-state EFV increased the 
average time-matched QTc intervals by 4.8 ms.12 This did not meet the mean 5.0 ms 
threshold defined by the United States Food and Drug Administration (FDA) adopted ICH 
E14 guidelines.13 The conflicting report of EFV-induced TdP and the thorough QT study 
suggest that some patients receiving EFV may be at greater risk for QT interval prolongation 
and TdP.11, 12, 14
Efavirenz is predominately eliminated by the cytochrome P450 (CYP) enzyme, CYP2B6, 
which is polymorphically expressed.15, 16 The CYP2B6*6 allele is associated with reduced 
EFV clearance and an increased incidence of EFV-induced CNS toxicity, hepatic injury, and 
treatment discontinuation.17–19 It follows that pharmacogenetic-based variability due to 
CYP2B6 polymorphisms may lead to a variability in EFV-induced QTc interval 
prolongation. However, the CYP2B6 genotype of patients was not assessed in the 
aforementioned report of EFV induced TdP or in the thorough QTc assessment.11, 12 The 
primary objective of this study was to evaluate EFV-associated QT interval changes with 
regard to CYP2B6 genotype and to explore mechanisms of QT interval lengthening. We 
hypothesized that CYP2B6 genetic variants that are known to slow EFV clearance would be 
associated with QTc interval lengthening.
Methods
Clinical Trial Study Design
The full inclusion and exclusion criteria and study design have been reported as part of a 
clinical trial designed to study the effect of steady state EFV on CYP substrates in healthy 
volunteers.20 Volunteers were included as subjects in the study if they were between 18 and 
49 years old, HIV negative, and confirmed to be healthy by physical and medical 
examination. All enrolled subjects provided written informed consent. The study was 
approved by the Institutional Review Board (IRB) at Indiana University Purdue University 
Indianapolis (IUPUI).
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The study followed a two-phase sequential design. In the first phase, subjects were 
administered a single EFV 600 mg dose orally with approximately 240 ml of water during a 
24-hour stay in the Indiana Clinical Research Center (ICRC). The second phase of the study 
was initiated 7 days following the first phase. In the second phase, subjects were given a 17-
day supply of EFV and instructed to take 600 mg daily, 2 hours before or after meals and 
close to bed time for 17 days. Blood samples were collected as outpatients on days 10, 13, 
16, 19, and 22 prior to EFV administration. During the single dose phase and on the last day 
of the second phase, ECGs were collected prior to EFV dosing and every 6 hours after that 
during the 24-hour inpatient stay in the ICRC. An hour after EFV administration in Phase I 
and the last day of Phase II, subjects received a single dose of an oral cocktail of cytochrome 
P450 (CYP) probes as part of the drug interaction study.20 Blood samples were serially 
collected from one arm through an indwelling venous catheter.
QT Interval Measurements
ECGs were recorded (Marquette Mac 5500, GE Healthcare Bio-Sciences, Pittsburgh, PA) at 
0, 6, 12, 18 and 24 hours following EFV administration after the first dose and at steady 
state achieved after the 17 daily doses. At each measurement point, at least 3 ECGs were 
recorded 1–3 minutes apart. QT and RR intervals were determined from leads II and V5 
manually by an investigator (AA) blinded to time, study phase, and genotype. Inter-
individual variability was assessed by an additional investigator (HJ) in a subset of ECGs 
(>500 complexes) using the kappa statistic. The reliability coefficient (i.e., kappa score) was 
92.6%. QT intervals were measured from the earliest QRS deflection to the end of the T 
wave. The end of the T wave was defined as the intersection of the terminal portion of the T 
wave and the isoelectric line. In each measured lead, QT and RR intervals were averaged 
over 5 consecutive beats to obtain a single mean QT interval from each lead from each ECG. 
To determine the QT interval at each time point, the mean QT interval from 3 ECGs at each 
time point were averaged for each of the measured leads. QT intervals were measured only 
from ECGs on which the end of the T wave was clearly discernible.
QT intervals were corrected using the Fridericia correction (QTcF). Time matched 
difference (TMD) in the QTcF interval between single and multiple EFV dosing at all 
recording time points (t) were calculated by subtracting QTcF intervals changes from 
baseline (ΔQTc) following single dose (SD) and at steady state (SS) based on equation 1.
(Equation 1)
The TMDs are presented as mean and 95% confidence intervals with significant QTcF 
interval prolongation defined as a mean TMD greater than 5.0 ms and an upper limit of the 
95% confidence interval greater than 10 ms per the ICH E14 guidelines.13
CYP2B6 Genotyping
Genomic DNA was extracted from human blood using standard protocol. DNA was 
genotyped for the G516T SNP in exon 4 (gene position 15631G>T; NCBI reference 
sequence: NG_000008.6) that leads to an amino acid change at codon 172 (Q172H) and for 
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the A785G SNP in exon 5 (gene position 18053A>G (NCBI reference sequence: 
NG_000008.6) that leads to an amino acid substitution (K262R), which together define the 
common CYP2B6*6 allele. Genotyping for the listed variants was performed by use of the 
pre-developed TaqMan Assay-Reagents Allelic Discrimination Kits (Applied Biosystems, 
Foster City, CA) according to the supplier's instructions as previously described.21 The allele 
specific PCR assays were run using the iQ SYBR Green Supermix using allele specific 
primers. TaqMan and allele specific PCR assays were run using an iCycler real-time PCR 
instrument. As a quality control and validation measure for these assays, additional 
genotyping was performed using a BioTrove Openarray™ chip SNP genotyping platform.
Analytical Methods
Concentrations of efavirenz, 8-hydroxyefavirenz (8-OH EFV), 7-hydroxyefavirenz (7-OH 
EFV) and 8,14-dihydroxyefavirenz (8,14-diOH EFV) in plasma were quantified using our 
previously described high performance liquid chromatography coupled with tandem mass 
spectrometry (LC-MS/MS) methods.22, 23
Chemicals
All chemicals for patch-clamp experiments were obtained from Sigma-Aldrich, including 
EFV (SML0536, Lot# 112M4701V). Stock solutions of 10 mg/ml EFV were prepared in 
dimethyl sulfoxide (DMSO), filtered, and stored in aliquots at −20 °C. Working solutions 
were freshly prepared at the time of the experiments by diluting the stock solution with the 
bath or pipette solution.
CYP2B6*1 cDNA transfection
The assessment of hERG-associated current (IhERG) was performed in human embryonic 
kidney (HEK) 293 cells, stably expressing hERG.24 Human CYP2B6*1 cDNA in a pCMV4 
vector was obtained as a gift from Dr. Ulrich Zanger.25 The hERG-HEK cells were co-
transfected with the purified CYP2B6*1 and GFP coding vector in a 5:1 ratio 
(CYP2B6:GFP) cDNA using Lipofectamine® 2000 reagent (Invitrogen) according to the 
manufacturer recommendations. Control cells were transfected with the GFP coding vector.
Cellular Electrophysiology
A set of whole-cell, voltage-clamp experiments were performed using a HEKA® EPC 9 
amplifier. Data were recorded and analyzed using HEKA® Patchmaster and Fitmaster 
software. At the time of the recordings, cell culture media was replaced by a bath solution 
(containing in mM; 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10 HEPES, and 10 glucose, pH 
adjusted to 7.4 with NaOH) containing different EFV concentrations (0.0, 0.1, 0.2, 0.4, 0.6, 
0.8, 1.0, 1.5 and 2.5 µg/mL). Borosilicate glass electrodes (tip resistant 2–5 MΩ) were filled 
with internal solution (containing in mM; 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP and 10 
HEPES, pH adjusted to 7.2 with KOH). Tail currents were measured at repolarizing test 
potentials (−100 to +40 mV, 4 seconds each) following a one second depolarizing step to 
+60 mV from a holding potential of −80 mV. Cell recordings were performed in a minimum 
2 plates (3–5 cells/plate) for each EFV concentration and compared to control.
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In hERG-HEK cells that were transiently transfected with CYP2B6*1 cDNA, tail current 
recordings were performed using the following 2-sweep voltage clamp protocol: membrane 
potential was held at −80 mV, increased to 60 mV (1 second), and currents were measured 
during two repolarizing steps at −100 and −20 mV (5 seconds each). This protocol was 
performed twice for each cell at 1 and 2 minutes following cytosolic access and exposure to 
EFV in the pipette solution in order to evaluate the influence of incubation time on EFV-
mediated alterations in hERG channel conductivity. A sigmoidal Emax model was fit to the 
EFV inhibitory effect on IhERG using Prism (GraphPad Software, Inc., La Jolla, CA).
Cytotoxicity Assay
In order to validate functional expression of CYP2B6 enzyme, transfected cells were 
incubated at 37°C with different cytotoxic concentrations of EFV. Cytotoxicity was assessed 
using a Trypan blue assay. Efavirenz concentrations were selected based on a kill curve that 
was developed to determine the EFV concentration that kills 50% of the hERG-HEK cells 
(LC50).
Data Analysis
The area under the EFV concentration-time curve from 0 to 24 hours (AUC0–24) was 
calculated using the linear trapezoidal rule. For multiple comparisons including the temporal 
changes in TMD and cellular electrophysiological data, the Shapiro-Wilk W test was used to 
check for normality of the data followed by a one-way ANOVA with Bonferroni correction 
or Dunnett’s test to determine statistically significant differences among different EFV 
concentrations or genotype, respectively. The EFV concentration that inhibited 50% of the 
maximal effect (IC50) was compared between groups using a t-test or ANOVA, as 
appropriate. The type I error rate for all analyses was set at 5%. Based on recent 
recommendations to enhance TQT studies, an exposure-response relationship was assessed 
between EFV concentrations and TMDs.26 A standard Emax model was fit to the TMDs 
versus EFV concentrations.
Results
Subject Demographics and Efavirenz Plasma Concentrations
Fifty-seven healthy subjects completed both phases of a two-phase sequential design that 
included a single oral EFV 600 mg dose (Single Dose, Phase I) and 17 days of oral EFV 600 
mg administration (Steady-State, Phase II). Subjects with the CYP2B6*1/*1 (n=34) and the 
CYP2B6*1/*4 (n=3) genotype were collectively grouped based on their phenotype of an 
EFV concentration-time profile similar to the wild-type metabolizers. Subjects with 
CYP2B6*1/*6 genotype (n=15) were considered intermediate EFV metabolizers, while 
subjects homozygous for CYP2B6*6 allele (n=5) represented the slow metabolizers. 
Demographic information for the study subjects stratified by CYP2B6 genotype are 
provided in Table 1.
Twenty-four hour exposure to EFV was not different among the CYP2B6 genotypes 
following the first oral EFV dose (p=0.14). Subjects carrying two CYP2B6*6 alleles 
displayed significantly higher EFV exposure at steady-state (p<0.05) than carriers of the 
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CYP2B6*1/*6 and CYP2B6*1/*1 with mean ± SD AUC0–24 (µg•hr/mL) of 152.9 ± 56.2, 
72.8 ± 14.1, and 58.22 ± 18.1, respectively as displayed in Figure 1.
QTcF Interval Changes and CYP2B6 Genotype
The QTcF, QT, and RR intervals did not change significantly from baseline following a 
single oral dose of EFV among the CYP2B6 genotypes (Supplemental Figure 1). Following 
steady-state EFV administration, the QTcF interval was not altered in carriers of the 
CYP2B6 *1/*1 or *1/*6 alleles (p>0.05 by repeated-measures ANOVA) but was 
significantly increased 6 hours following EFV administration in the *6/*6 carriers from a 
mean ± SD baseline of 406 ± 16.4 to 423 ± 11.8 ms (p<0.05 by Dunnett’s test) with an 
overall p value of 0.02 from the repeated-measures ANOVA (Figure 2A). The RR intervals 
and the unadjusted QT intervals did not significantly change at steady state (Figures 2B and 
2C) with an overall p value > 0.05.
Given the lack of change in the QTcF interval following a single dose and the significant 
accumulation of EFV given its long half-life (~50 hours), time matched differences (TMD) 
from baseline in QTcF intervals were corrected between the single and multiple EFV dosing 
at all recording time points. In the pooled study population, the mean TMD in lead II was 
decreased for every time measured following EFV administration (Figure 3A). However, a 
gene-response relationship was observed with the largest TMD in subjects homozygous for 
the CYP2B6*6 allele (Figure 3B and Table 2). The grouped TMD versus EFV concentration 
data was best fit to a standard Emax model with an estimated mean ± SEM half maximal 
inhibitory concentration (IC50) of 7.3 ± 0.5 µg/mL and maximum effect of 10 ± 4.2 ms 
(Figure 3C).
The CYP2B6 *6/*6 allele carriers demonstrated the highest EFV concentrations and had a 
positive relationship between TMD and EFV concentration among CYP2B6*6/*6 allele 
carriers (β=0.0026, p=0.0497) in the linear model. There was no observed relationship 
between TMD and EFV concentrations in CYP2B6*1/*6 allele carriers or the 
CYP2B6*1/*1 allele carriers (β =−0.003, p=0.083). Additionally, there was no observed 
relationship between TMD and 8-OH, 7-OH, or 8,14-diOH EFV concentrations in 
CYP2B6*1/*1 allele carriers, CYP2B6*1/*6 allele carriers or CYP2B6*6/*6 allele carriers 
using linear models (data not shown).
Efavirenz-Associated IHERG Changes
Current-voltage relationships were elicited in HEK293 cells stably expressing hERG using 
the whole-cell voltage clamp technique following treatment with various EFV 
concentrations applied to the culture media or directly to the internal (pipette) or external 
(bath) solutions. Efavirenz 0.2 µg/mL, 0.8 µg/mL and 2.5 µg/mL inhibited both inward and 
outward IhERG currents in a concentration-dependent manner when applied to the bath 
solution (Figure 4). EFV also inhibited inward and outward IhERG when applied to the 
culture media for 24 hours. As expected, the EFV concentration-IhERG and cytotoxicity 
relationship was shifted when EFV was applied to the culture media since it contains fetal 
bovine serum (FBS) and EFV is greater than 99.5% protein bound (data not shown).
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The mean ± standard error of the mean (SEM) maximum observed inhibition of the hERG-
related current was 70.7 ± 7.0 percent at 2.5 µg/mL in the bath solution. Sigmoidal 
concentration-response curves were fit to the EFV-associated inhibition of the inward and 
outward IhERG currents recorded at −100 mV and −20 mV, respectively (Figure 5). The 
estimated mean ± SEM maximum inhibition (Emax) was 55.3 ± 3.5%; IC50 was 0.17 ± 0.15 
µg/mL; and Hill factor was 7.7 ± 14.4 at −20 mV while at −100 mV the Emax was 92.1 
± 255 %; the IC50 was 1.95 ± 3.23 µg/mL and the Hill factor was 0.79 ± 1.75.
CYP2B6 effect on Efavirenz-Associated IhERG Changes
Given the altered relationships between EFV concentrations and TMD among CYP2B6 
genotypes, we assessed the potential contributions of EFV metabolites formed by the 
CYP2B6 isoenzyme to influence IhERG. To assess the potential IhERG effects by EFV 
metabolites formed by the CYP2B6 pathway, EFV induced IhERG inhibition was assessed in 
cells transiently transfected with functional CYP2B6*1 and GFP cDNA versus GFP alone. 
The LC50 for EFV was estimated to be 10.48 ± 0.43 µg/mL at 24 hours and 6.93 ± 0.05 
µg/mL at 48 hours in hERG-HEK cells; as displayed by the kill curves in Supplemental 
Figure 2A. Cells expressing CYP2B6*1 demonstrated significantly less cytotoxicity 
following 24 and 48 hours incubation with EFV (Supplemental Figures 2B and 2C). This 
suggests that the cells expressed functional CYP2B6 protein following transient transfection.
The percent IhERG inhibition at −20 mV was similar in CYP2B6-transfected cells following 
1 minute of exposure to that of cells that expressed GFP only (Figure 6A). However, when 
holding the cells for 2 minutes, there was an observed right-shift in the concentration-effect 
curve in the same CYP2B6-transfected cells. This resulted in significantly less IhERG 
inhibition at 0.4 µg/mL in the cells expressing CYP2B6 (Figure 6B). This right shift in the 
concentration-effect relationship suggest that IhERG inhibition is diminished as parent EFV 
is metabolized by CYP2B6 in this system.
Discussion
In 2005, the FDA adopted the ICH recommendation of clinical TQT studies to investigate 
the drug-induced, heart rate corrected QT interval prolongation potential.13 The results of 
this study indicate that EFV prolongs the QTcF interval beyond the E14 threshold in healthy 
subjects that are carriers of two copies of the CYP 2B6*6 allele while demonstrating a direct 
concentration-response relationship. The EFV mediated prolongation of the QTcF interval 
may be due to its ability to inhibit IhERG as demonstrated in stably transfected hERG-HEK 
cells.
A TQT study has previously been conducted for steady-state EFV using a 600 mg once daily 
regimen in 60 healthy subjects with an unreported CYP2B6 genotype.12 The TMD in QTcF 
intervals peaked at 6 hours following EFV administration. The peak TMD was 5.0 ms with 
an upper limit of the 95% CI just above 8.0 ms, which did not meet the E14 threshold.12 
Since there was no available information regarding CYP2B6 genotype in the previous TQT 
study, the number of CYP2B6*6 carriers cannot be determined. Of note, there were no 
African American subjects included in the previously reported TQT study with 59 reported 
as Hispanic or white non-Hispanic and one was reported as an American Indian or Alaskan 
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native.12 The lack of African American subjects may be important since the CYP2B6*6 
allele frequency has been reported to range between 8–37% in Caucasian and Hispanic 
populations and up to 65% in African populations.27 Given the ethnic and race distribution, 
it is likely that a small portion of patients were carriers of the CYP2B6*6 allele in the 
previously reported TQT study with even fewer being homozygous for the variant allele.
The propensity for EFV to provoke TdP is not known. A case report indicates EFV was 
associated with remarkable QTc prolongation (580 ms) and tachyarrhythmia in an African 
American HIV patient.11 The association of EFV and a prolonged rate corrected QT interval 
in this case report was based on the absence of other risk factors and the resolution of QTc 
interval prolongation and tachyarrhythmias following drug discontinuation.11 The CYP2B6 
genotype of that patient was not known but the fact that he was African American increases 
the likelihood that the patient was a CYP2B6*6 carrier.
The current report and several previously reported studies demonstrate a strong association 
between the CYP2B6*6/*6 genotype and increased EFV exposure through decreased parent 
drug clearance.15, 16 The mean Cmax was reported to be approximately 5.0 µg/mL in the 
TQT study and was 4.1, 4.5 and 7.6 µg/mL among CYP2B6*1/*1, *1/*6 and *6/*6 
respectively in the current report. A therapeutic window of EFV between 1 to 4 µg/mL has 
been suggested, with higher concentrations of up to 26 µg/ml being reported in HIV patients 
with EFV associated CNS toxicity.17
Most drugs that clinically prolong the QTc interval are inhibitors of the rapid component of 
the delayed rectifier current which is encoded by the hERG gene.28 A concentration-
dependent inhibition of IhERG by EFV was observed with an IC50 estimated to be 
approximately 0.2 µg/mL (i.e. unbound EFV IC50). However, EFV is greater than 99.5% 
protein bound and the IC50 was estimated to be approximately 2.0 µg/mL in the culture 
media. The observed concentration-response relationship and the gene-dose effect in the 
clinical trial coupled with the in vitro demonstration of EFV induced hERG inhibition were 
important findings to support the observed QTc prolongation in the relatively small number 
of CYP2B6*6 homozygotes.
Limitations
The clinical study was not designed as a TQT study and did not incorporate a positive 
control arm. A traditional TQT study would assess TMDs between a placebo phase and a 
steady-state phase. In this study, the time matched differences in QTcF were assessed 
between a single dose of EFV and steady-state EFV phase. The long half-life and 
accumulation potential of EFV limits the likelihood that this design had an impact on the 
final conclusions. In fact, the concentration-QTcF interval response did not show a positive 
relationship until EFV concentrations were greater than 4 µg/mL. These concentrations are 
not achieved following a single dose of EFV. Nonetheless, if using TMD between the single 
dose and steady state phases were to confound our findings, it would decrease the ability to 
find a QTc prolonging effect with EFV.
An additional limitation due to the clinical study design was the administration of a CYP 
substrate cocktail. The influence of this cocktail on the results should be negligible since it 
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was administered as a single dose in both study phases, 1 hour following EFV 
administration and included drugs that have not been associated with QTc interval 
prolongation; caffeine, midazolam, omeprazole and tolbutamide.29 Furthermore, omeprazole 
and midazolam concentrations were decreased in the steady-state EFV phase and 
tolbutamide and caffeine were unaltered.20 Therefore, the differences in the QTcF interval 
are not likely due to the drugs in the cocktail.
Conclusions
This study has uncovered the potential risk for QTc interval prolongation associated with 
EFV in CYP2B6*6/*6 carriers. The mechanism may be due to inhibition of the hERG-
related current which was demonstrated through an in vitro system in this study. Prompted 
by the results of these findings, a TQT study is being performed by the manufacturer that 
will incorporate CYP2B6 genotype (ClinicalTrials.gov #NCT02164812). The full potential 
of EFV to prolong the QTc interval cannot be fully verified until the conclusion of that 
study.
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Figure 1. 
Mean ±SD efavirenz AUC0–24 (µg•hr/mL) following a single dose (600 mg) and at steady-
state among CYP2B6 genotype groups *1/*1 (n=36), *1/*6 (n=14), and *6/*6 (n=5). 
*indicates p<0.05
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Figure 2. 
Mean ± SD (a) QTcF intervals; (b) RR intervals; and (c) uncorrected QT intervals following 
a 600 mg dose of EFV at steady state (i.e., following 17 doses of EFV 600 mg) among the 
CYP2B6 genotypes; (d) representative lead II ECG tracing (25 mm/s paper speed) of 3 
consecutive beats following a 600 mg dose of EFV at steady state (upper trace) and a single 
dose (lower trace) in a CYP2B6*6/*6 patient with an average QTcF increase from 397 ms to 
425 ms. The mean QTcF interval was significantly increased 6 hours following steady-state 
EFV administration in the CYP2B6*6/*6 group. The overall p value from the repeated 
measures ANOVA was equal to 0.02.
*indicates p<0.05 versus time zero
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Figure 3. 
Mean ± 95% confidence intervals of QTcF time-matched difference (ΔΔQTc) at steady-state 
versus single dose for (a) pooled study population and (b) among CYP2B6 genotype groups 
(*1/*1 (n=36), *1/*6 (n=14), and *6/*6 (n=5)). The shaded area represents the difference 
between a 0 ms and the upper 95% CI threshold of 10 ms defined by the E14 guidance for 
thorough QT studies. This threshold is exceeded at 6, 12, and 18 hours post EFV dose 
among the CYP2B6*6/*6 genotype (C) the mean and 95% CI of TMD were grouped in 
deciles based on EFV concentrations of the pooled population and fit to a standard Emax 
model for the exposure-response analysis.
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Figure 4. 
hERG current recordings following a fifteen-sweep voltage clamp protocol (a) displaying 
representative current recordings following exposure to EFV 0.0 (Control), 0.2, 0.8, and 2.5 
µg/ml and (b) Mean ± standard error of the mean (SEM) corrected current–voltage 
relationship of hERG current following EFV concentrations (0.0–2.5 µg/ml) applied to the 
bath solution. EFV concentrations exceeding 0.4 µg/mL significantly inhibited outward 
hERG tail currents (overall P<0.0001).
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Figure 5. 
Concentration-response curve of maximal (a) inward hERG current inhibition at −100 mV 
and (b) outward hERG current inhibition at −20 mV following exposure to EFV 0.0–2.5 
µg/mL in the bath solution. The open circles represent the mean inhibition % while the error 
bars represent the SEM. The data were fit to the sigmoidal Emax model with the 
concentration-response curves represented by the best fit line.
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Figure 6. 
Concentration-response curves of outward IhERG inhibition following exposure to EFV 0.0–
0.8 µg/mL in the pipette solution. The mean ± SEM percent inhibition of outward current in 
CYP2B6-GFP (□) and cDNA (○) transfected cells are displayed at (a) 1 minute and (b) 2 
minutes following EFV exposure.
*indicates p<0.05
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Table 1
Summary of demographic information
CYP2B6 Genotype
*1/*1 or *1/*4 *1/*6 *6/*6
n=37 (65%) n=15 (26%) n=5 (9%)
Sex
Male 22 (59%) 11 (73%) 2 (40%)
Female 15 (41%) 4 (27%) 3 (60%)
Race
White 28 (76%) 10 (67%) 3 (60%)
Black 8 (22%) 2 (13%) 2 (40%)
Asian 0 (0%) 2 (13%) 0 (0%)
Indian 1 (2%) 1 (7%) 0 (0%)
Weight (Kg, mean ± SD) 73 ± 13 79 ± 15 65 ± 5
Age (Years, mean ± SD) 28 ± 10 29 ± 9 23 ± 4
BMI (Kg/m2, mean ± SD) 24 ± 4 26 ± 4 21 ± 3
*
Data presented as number (percent) or mean ± standard deviation
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Table 2
Mean (95% CI) time matched difference in QTcF, (ms)
Lead II
CYP2B6 genotype
Pooled Sample *1/*1 *1/*6 *6/*6
Time (h) (n = 57) (n = 37) (n = 15) (n=5)
0 −0.1 (−0.2; 0.0) 0 (−0.2; 0.1) −0.2 (−0.4; 0) −0.2 (−0.4; 0)
6 −5 (−10; 0) −11 (−18; −4) 2 (−5; 9) 14 (2; 27)†
12 −3 (−9; 4) −6 (−15; 3) −1 (−9; 7) 18 (−4; 40)†
18 −7 (−16; 2) −9 (−23; 4) −7 (−16; 2) 6 (−2; 14)†
24 −2 (−10; 5) −3 (−15; 8) −1 (−7; 6) 1 (−12; 13)
†indicates IEC threshold has been exceeded
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